Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

• Henrik H. Hansen ,

  Contributed equally to this work with: Henrik H. Hansen, Katrine Fabricius

  * E-mail: hbh@gubra.dk (HHH); niels@gubra.dk (NV)

  Affiliation Gubra, Agern Allé 1, DK-2970 Hoersholm, Denmark

  ⨯
• Katrine Fabricius ,

  Contributed equally to this work with: Henrik H. Hansen, Katrine Fabricius

  Affiliation Gubra, Agern Allé 1, DK-2970 Hoersholm, Denmark

  ⨯
• Pernille Barkholt,

  Affiliation Gubra, Agern Allé 1, DK-2970 Hoersholm, Denmark

  ⨯
• Pernille Kongsbak-Wismann,

  Affiliation Gubra, Agern Allé 1, DK-2970 Hoersholm, Denmark

  ⨯
• Chantal Schlumberger,

  Affiliation Gubra, Agern Allé 1, DK-2970 Hoersholm, Denmark

  ⨯
• Jacob Jelsing,

  Affiliation Gubra, Agern Allé 1, DK-2970 Hoersholm, Denmark

  ⨯
• Dick Terwel,

  Affiliation reMYND NV, Gaston Greenslaan 1, B-3001 Leuven-Heverlee, Belgium

  ⨯
• Annelies Termont,

  Affiliation reMYND NV, Gaston Greenslaan 1, B-3001 Leuven-Heverlee, Belgium

  ⨯
• Charles Pyke,

  Affiliation Diabetes Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark

  ⨯
• Lotte Bjerre Knudsen,

  Affiliation Diabetes Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark

  ⨯
• Niels Vrang

  * E-mail: hbh@gubra.dk (HHH); niels@gubra.dk (NV)

  Affiliation Gubra, Agern Allé 1, DK-2970 Hoersholm, Denmark

  ⨯